Guardant Complete

Backed by >80 clinical outcomes studies
and >400 peer-reviewed publications.

    • Clinical Utility of Comprehensive Cell-Free DNA Analysis to Identify Genomic Biomarkers in Patients With Newly Diagnosed Metastatic Non-Small Cell Lung Cancer

      Leighl NB, et al. Clin Cancer Res. 2019

      Read more ›
    • Clinical Outcomes for Plasma-Based Comprehensive Genomic Profiling Versus Standard-of-Care Tissue Testing in Advanced Non-Small Cell Lung Cancer

      Page RD, et al. Clin Lung Cancer. 2022

      Read more ›
    • Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non-Small Cell Lung Cancer

      Aggarwal C, et al. JAMA Oncol. 2019

      Read more ›
    • Cell-Free DNA (cfDNA) Testing in Lung Adenocarcinoma (LUAC) Patients: Spanish Lung Liquid Versus Invasive Biopsy Program (SLLIP)

      Palmero R, et al. J Thorac Onc. 2018

      Read more ›
    • Up-Front Cell-Free DNA Next Generation Sequencing Improves Target Identification in UK First Line Advanced Non-Small Cell Lung Cancer (NSCLC) Patients

      Cui W, et al. Eur J Cancer. 2022

      Read more ›